An­oth­er win for Novo's semaglu­tide? Physi­cians pre­fer it most in the emerg­ing field of NASH treat­ments, sur­vey finds

As fat­ty liv­er dis­ease gets a new name, will it al­so fi­nal­ly get ap­proved drug treat­ments?

That’s what health­care pro­fes­sion­als are hop­ing for as non­al­co­holic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER